Tranzyme Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2013 | $28 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jul 2013 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jun 2010 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tranzyme Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).
SEC Form D · Nov 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2013
That is all the official record says: Tranzyme Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| BDC Capital Inc. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Capital regional et cooperatif Desjardins | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Hig GP II Inc | Company | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| H.I.G. Ventures - Tranzyme, LLC | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Quaker Bioventures Capital LP | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Quaker Bio Ventures LP | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Thomas, McNerney & Partners, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Thomas Mcnerney & Partners LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| TMP Associates LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| TMP Nominee, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David S Moore | Executive officer | Nov 2013 |
| Jeryl L Hilleman | Executive officer | Nov 2013 |
| Dana S. McGowan | Executive officer | Jul 2013 |
| David S. Moore | Executive officer | Jul 2013 |
| Franck S. Rousseau | Executive officer | Jul 2013 |
| Linda S. Grais | Executive officer | Jul 2013 |
| Richard I. Eisenstadt | Executive officer | Jun 2010 |
| Vipin K. Garg | Executive officer | Jun 2010 |
| Anne M VanLent | Director | Nov 2013 |
| Eckard F Weber | Director | Nov 2013 |
| Franck S Rousseau | Director | Nov 2013 |
| Jean-Paul G Castaigne | Director | Nov 2013 |
| Lars G Ekman | Director | Nov 2013 |
| Linda S Grais | Director | Nov 2013 |
| Michael F Powell | Director | Nov 2013 |
| Nina L Kjellson | Director | Nov 2013 |
| Pratik F Shah | Director | Nov 2013 |
| Anne M. VanLent | Director | Jul 2013 |
| Eckard F. Weber | Director | Jul 2013 |
| Franck S. Rousseau | Director | Jul 2013 |
| Jean-Paul F. Castaigne | Director | Jul 2013 |
| Lars F. Ekman | Director | Jul 2013 |
| Linda S. Grais | Director | Jul 2013 |
| Michael F. Powell | Director | Jul 2013 |
| Nina S. Kjellson | Director | Jul 2013 |
| Pratik F. Shah | Director | Jul 2013 |
| Aaron F. Davidson | Director | Jun 2010 |
| Alex D. Zisson | Director | Jun 2010 |
| Brenda D. Gavin | Director | Jun 2010 |
| David J. Drutz | Director | Jun 2010 |
| Donald F. Corcoran | Director | Jun 2010 |
| Jean-Paul K. Castaigne | Director | Jun 2010 |
| Vipin K. Garg | Director | Jun 2010 |